Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several core mechanistic and indication statements match the provided label excerpts for Omeprazole and Sodium Bicarbonate; however, multiple claims are unsupported or overgeneralized relative to the supplied labeling (notably comparisons to H2 blockers and side-effect specificity).
Category Scores
Accurate Statements
Omeprazole is a proton pump inhibitor used to treat conditions such as heartburn, stomach ulcers, and gastroesophageal reflux disease (GERD).
Indications include treatment of heartburn and other GERD symptoms; short-term treatment of active duodenal ulcer and active benign gastric ulcer; treatment of EE due to acid-mediated GERD. (Section 1 INDICATIONS AND USAGE)
Omeprazole works by decreasing the amount of acid produced in the stomach.
Mechanism: suppresses gastric acid secretion via specific inhibition of the H+/K+ ATPase; blocks final step of acid production leading to inhibition of basal and stimulated acid secretion. (Section 12.1)
Omeprazole is prescribed for healing erosive esophagitis.
Indications include short-term treatment (4 to 8 weeks) of EE and maintenance of healing of EE due to acid-mediated GERD. (Section 1 INDICATIONS AND USAGE)
Omeprazole is used to treat duodenal ulcers.
Short-term treatment of active duodenal ulcer. (Section 1 INDICATIONS AND USAGE)
Omeprazole is used to treat gastric ulcers.
Short-term treatment (4 to 8 weeks) of active benign gastric ulcer. (Section 1 INDICATIONS AND USAGE)
Omeprazole is used to manage Zollinger-Ellison syndrome.
Not supported by provided label excerpts; therefore listed under unsupported statements below. (No label support in provided sections.)
Omeprazole belongs to the class of proton pump inhibitors (PPIs).
Label refers to PPIs; mechanism describes it as a gastric acid-pump inhibitor (H+/K+ ATPase inhibition). (Sections 5 and 12.1)
Omeprazole irreversibly blocks the H+/K+ ATPase enzyme system (the proton pump) in gastric parietal cells.
Mechanism section: inhibition of the H+/K+ ATPase; pharmacodynamics: irreversible binding to the parietal H+/K+ ATPase. (Sections 12.1 and 12.2)
Omeprazole inhibits the final step of acid production.
Mechanism: blocks the final step of acid production. (Section 12.1)
Omeprazole reduces the secretion of hydrochloric acid into the stomach lumen.
Mechanism describes inhibition of gastric acid secretion by H+/K+ ATPase inhibition and inhibition of basal/stimulated acid secretion. (Section 12.1)
Unsupported Statements
Omeprazole is used to manage Zollinger-Ellison syndrome.
No indication for Zollinger-Ellison syndrome appears in the provided label excerpts (Section 1).
Common side effects of omeprazole can include diarrhea, nausea, vomiting, stomach pain, and constipation.
The provided label excerpts for adverse reactions list only serious adverse reaction categories/headers and do not support this specific set of common side effects. (Section 6 excerpt does not include these statements.)
Less common side effects of omeprazole may include dizziness, rash, and headache.
The provided label excerpts do not support this specific list of less common side effects. (Section 6 excerpt does not include these statements.)
Proton pump inhibitors are generally more potent in reducing stomach acid production compared to H2 blockers like ranitidine or famotidine.
No comparison to H2 blockers (ranitidine/famotidine) is provided in the supplied label excerpts. (Sections provided do not include such a statement.)
Information regarding specific patent expiry dates for Glenmark Pharmaceuticals' omeprazole products is not readily available in the provided context.
This is a non-label factual statement about patent information availability and is not supported or addressed by the provided label excerpts.
Patent protection for omeprazole has expired in many regions, leading to the availability of generic versions.
Patent/generic availability statements are not addressed in the provided label excerpts.
Other pharmaceutical companies can manufacture and market generic versions of omeprazole provided they meet regulatory requirements.
Generic manufacturing/marketing statements are not addressed in the provided label excerpts.
Expiry of patents can lead to increased competition and lower prices for omeprazole.
Price/competition implications of patent expiry are not addressed in the provided label excerpts.
Contradictions
Important Omissions
No mention of contraindications specific to the provided label (e.g., hypersensitivity to substituted benzimidazoles/components; contraindication with rilpivirine-containing products).
Importance:
Moderate
No mention of key warnings/precautions present in the provided label excerpts (e.g., acute tubulointerstitial nephritis; sodium bicarbonate-related acid-base considerations; C. difficile-associated diarrhea risk; interaction with clopidogrel; hypomagnesemia monitoring).
Importance:
Moderate
No dosage/regimen details by indication (including that recommended doses are based upon omeprazole content) and no administration instructions (e.g., swallow capsules intact; take empty stomach at least 1 hour before meals; suspension/NG-OG tube feeding timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about side-effect frequency and non-label claims (Zollinger-Ellison, H2 comparison, patent/pricing) could mislead interpretation of safety/appropriateness; additionally, omission of contraindications and warnings increases risk of incomplete label-aligned information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are unsupported by the provided label excerpts, including Zollinger-Ellison indication and specific side-effect lists; also includes non-label patent/pricing assertions.
Suggested Improvement
Restrict claims to the provided label’s listed indications (active duodenal ulcer, benign gastric ulcer, short-term GERD symptoms/EE, EE maintenance; and critically ill reduction of risk of upper GI bleeding) and supported mechanism/irreversibility statements; remove or qualify unsupported side-effect frequency comparisons; omit non-label patent/pricing statements; include label contraindications and key warnings from the provided sections.